AlphAIalphai — Financial news for AI agents
BenzingaNOV 242 min read$ORIC

ORIC® Pharmaceuticals to Participate in the 8th Annual Evercore Healthcare Conference - ORIC Pharmaceuticals (NASDAQ:ORIC)

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Nov. 24, 2025 ( GLOBE NEWSWIRE ) -- ORIC Pharmaceuticals, Inc. ( NASDAQ:ORIC ) , a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that management will be participating ...

Original reporting
Benzinga · Globe Newswire
Published Nov 24, 2025, 9:05 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Nov 24, 2025, 10:00 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
ORIC® Pharmaceuticals to Participate in the 8th Annual Evercore Healthcare Conference - ORIC Pharmaceuticals (NASDAQ:ORIC) — source image
Source · www.benzinga.com
Decision brief

The 30-second read

$ORICNeutralLow
01

Why it matters

Participation in the conference indicates active engagement but lacks immediate news catalysts.

02

Market read

The event is relevant for biotech investors; potential for short-term price movement.

03

What to watch

Potential delays in clinical trials or regulatory setbacks could offset positive sentiment.

Timing: short-term

Background

ORIC Pharmaceuticals is a clinical-stage oncology company focusing on mechanisms of therapeutic resistance.

Company-level read

Ticker impact

$ORICNeutralMedium confidence
Context

The news pertains to ORIC Pharmaceuticals' participation in a healthcare conference, indicating potential corporate developments.

Expected impact

Moderate positive movement expected in the short term.

Evidence & confidence

Conference participation often signals active engagement and potential updates, but no immediate product news is provided.

$EVRNeutralHigh confidence
Context

The news mentions EVR in the sentiment analysis, but its direct relevance to the event is minimal.

Expected impact

Negligible impact.

Evidence & confidence

Relevance score is low (0.165), indicating minimal influence on EVR's stock.

Market effects

Sector

Potential positive sentiment in the biotech and healthcare sectors due to ongoing clinical developments.

Regional

Limited regional impact; event is US-based.

Global

Moderate, as biotech conferences attract international attention.

Counterpoint

What could challenge this read

The conference participation may be a routine event with no immediate catalysts, thus limiting short-term trading opportunities.

Key entities

  • Company
    ORIC Pharmaceuticals

    A biotech firm developing treatments for cancer resistance.

  • Event
    Evercore Healthcare Conference

    A platform for biotech and healthcare companies to present updates.

Read at source← All news

Related articles

AUG 3
$ORICMed

Oric Pharmaceuticals, Inc. (ORIC): Results of Operations and Financial Condition

Oric Pharmaceuticals, Inc. (ORIC) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 oric-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 ORIC ® Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Updates Initiated Himalayas-1 global Phase 3 trial in patients with mCRPC previously treated with abiraterone Entered into a clinical trial

SEC EDGAR 8-K6 min
JUL 30
$EVRMedAI 8/10

EVR Q2 FY2026 earnings call — BigGo Finance

Evercore (EVR) reported Q2 FY2026 adjusted net revenues of $1.0B (+19% YoY) and adjusted diluted EPS of $2.91 (+20% YoY). First-half 2026 revenues were $2.4B (+56%). Underwriting rose 201% YoY to $97M, and Wealth Management AUM reached $16.2B. Management cited near-record backlogs and expected full-year non-comp ratio near 14.2%, plus $734M buybacks YTD.

finance.biggo.com7 min
JUL 29
$EVRMedAI 9/10

Evercore Inc. (EVR): Results of Operations and Financial Condition

Evercore Inc. (EVR) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 earningsrelease2q26.htm EX-99.1 Document Exhibit 99.1 E V E R C O R E EVERCORE REPORTS SECOND QUARTER 2026 RESULTS; QUARTERLY DIVIDEND OF $0.89 PER SHARE Second Quarter Results Year to Date Results U.S. GAAP Adjusted U.S. GAAP Adjusted Q2 2026 Q2 2025 Q2 2026 Q2 2025 YT

SEC EDGAR 8-K6 min
JUL 23
$NSCMed

Evercore ISI raises Norfolk Southern stock price target on earnings beat By Investing.com

Evercore ISI raised its price target for Norfolk Southern (NYSE:NSC) to $358 from $325 and kept an “In Line” rating after the company’s adjusted Q2 2026 EPS of $3.52. Revenue beat expectations, but higher employee costs hurt the operating ratio. Evercore lifted 2026 EPS to $13.26 and 2027 to $14.60, citing Union Pacific and Canadian National merger-related agreements.

m.investing.com4 min
JUL 16
$PYPLHighAI 9/10

PayPal is working with Goldman, Evercore as suitors circle

PayPal Holdings is working with advisers Goldman Sachs and Evercore to review strategic options, including a potential sale or breakup, according to people familiar with the matter. Stripe and Advent are pursuing a $50 billion-plus takeover and have offered about $60 per share, backed by about $50 billion in financing, Reuters reported. PayPal shares rose up to 17% to $54.98.

reporterherald.com6 min